Skip to content
ImmunoACT logo — India's Leader in Cell & Gene Therapies

ImmunoACT

India's Leader in Cell & Gene Therapies

Founded 2018 India Navi Mumbai, India 99 employees Corporate Round Total: $1.40B Biotechnology

General Information

Company Name ImmunoACT
Founded Year 2018
Location India Navi Mumbai, India
Employees 99
Industries Biotechnology
Funding Stage Corporate Round
Social

BounceWatch is an independent company data service, not affiliated with ImmunoACT. To contact ImmunoACT, visit ImmunoACT.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does ImmunoACT compare?

A PDF of ImmunoACT and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting ImmunoACT soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About ImmunoACT

ImmunoACT is a pioneering biotechnology startup, proudly based in India, that specializes in the development of indigenous Cell & Gene Therapy. Founded in 2018 as a spin-out from IIT-Bombay, the company has quickly established itself as a leader in the field, with a strong focus on addressing unmet medical needs within the country. Their mission revolves around providing affordable access to novel autologous CAR-T cell therapies to a broader patient population, starting with blood cancers. The company has seen significant support from investors, with the latest corporate round investment totaling a substantial INR800.00M, confirmed on 31 May 2023. This injection of funds came from Laurus Labs, consolidating their commitment to ImmunoACT's vision and potential to make a meaningful impact in the biotechnology landscape. ImmunoACT's dedication to innovation and disrupting the status quo in healthcare has positioned them as an attractive prospect for venture capital firms seeking opportunities in the biotechnology sector. As they continue to expand their pipeline and make strides in pioneering cell and gene therapies, their trajectory will undoubtedly be closely monitored by investors looking to align with pioneering ventures in the field.

Business keywords: Cell therapy, Gene therapy, IIT-Bombay, Startup, Translational research, Viral vector process development, Autologous CAR-T cell therapies, Blood cancers, Healthcare innovation, Drug development, Medical advancements

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Secondary Market INR40.00M -
31 May 2023
Corporate Round INR800.00M 1
Laurus Labs
31 May 2023
Corporate Round INR557.50M 1
Laurus Labs
19 Nov 2021

ImmunoACT Alternatives & Competitors

View All Alternatives
ImmunoACT vs
Excellos
Excellos United States

A unique full-service CDMO, setting new standards in Cell & Gene Therapy

Corporate Round
38 employees
Biotechnology, Health Care
ImmunoACT vs
RoslinCT
RoslinCT United Kingdom

Your Advanced Cell & Gene Therapy CDMO Partner

Private Equity
350 employees
Biotechnology, Manufacturing
ImmunoACT vs

Nanomechanical Gene Delivery to Transform the Engineering of Cell Based Therapies

Seed
5 employees
Biopharma, Biotechnology

FAQ About ImmunoACT

India's Leader in Cell & Gene Therapies
ImmunoACT was founded in 2018.
ImmunoACT is headquartered in Navi Mumbai, India.
ImmunoACT operates in Biotechnology. Its work centres on Cell therapy, Gene therapy, IIT-Bombay and Startup.
ImmunoACT has approximately 99 employees.
ImmunoACT has completed 3 funding rounds, raising a total of $1.40B. The latest funding stage is Corporate Round.
Top alternatives and competitors to ImmunoACT include Excellos, RoslinCT, Basilard BioTech, Inc., Prescient Therapeutics, eXmoor pharma. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
ImmunoACT and Excellos are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for ImmunoACT, https://bouncewatch.com/company/immunoact, updated 28 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout